Literature DB >> 843419

Acute haemodynamic effects of metoprolol in hypertensive patients.

R Sannerstedt, H Wasir.   

Abstract

1. The acute haemodynamic effects of metoprolol (0.15 mg/kg body weight) intravenously were studied at rest and during exercise, in a recumbent position in five patients with arterial hypertension of WHO Stage 1 or 2. 2. Significant decreases in heart rate, cardiac output and arterial blood pressures, both at rest and during exercise, were seen. There were no changes in the calculated stroke volume or systemic vascular resistance. 3. The apparent absence of any relative preponderance of the alpha-adrenoreceptors after acute beta-adrenoreceptor blockade with metoprolol warrants further studies on metoprolol in arterial hypertension.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 843419      PMCID: PMC1428982          DOI: 10.1111/j.1365-2125.1977.tb00661.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  4 in total

Review 1.  A survey of the pharmacological properties of metoprolol in animals and man.

Authors:  B Ablad; K O Borg; E Carlsson; L EK; G Johnson; T Malmfors; C G Regårdh
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

2.  Influence of metoprolol and propranolol on hemodynamic effects induced by adrenaline and physical work.

Authors:  G Johnsson
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

3.  Comparative hemodynamic studies in man of adrenergic bepta-1-receptors agents without (h 93/26 equal to metoprolol) or with (h 87/07) intrinsic sympathicomimetic activity.

Authors:  J Stenberg; H Wasir; A Amery; R Sannerstedt; L Werkö
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

4.  Hemodynamic responses to tilt and beta-adrenergic blockade in young patients with borderline hypertension.

Authors:  R Sannerstedt; S Julius; J Conway
Journal:  Circulation       Date:  1970-12       Impact factor: 29.690

  4 in total
  5 in total

1.  Metoprolol--a new cardioselective beta-adrenoceptor blocking agent for treatment of tachyarrhythmias.

Authors:  H S Wasir; R K Mahapatra; M L Bhatia; S B Roy; R Sannerstedt
Journal:  Br Heart J       Date:  1977-08

Review 2.  Metoprolol: a review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris.

Authors:  R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1977-11       Impact factor: 9.546

3.  How intrinsic sympathomimetic activity modulates the haemodynamic responses to beta-adrenoceptor antagonists. A clue to the nature of their antihypertensive mechanism.

Authors:  A J Man in 't Veld; M A Schalekamp
Journal:  Br J Clin Pharmacol       Date:  1982       Impact factor: 4.335

4.  Maximal exercise power after a single dose of metoprolol and of slow-release metoprolol.

Authors:  H Folgering; M van Bussel
Journal:  Eur J Clin Pharmacol       Date:  1980-10       Impact factor: 2.953

5.  Metabolic aspects of maximal exercise performance after slow release metoprolol and after atenolol.

Authors:  H T Folgering; J F Borm; R H van Haaren
Journal:  Eur J Clin Pharmacol       Date:  1982-10       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.